TransEnterix (NYSE:TRXC) said last week that it won 510(k) clearance from the FDA for its Senhance robot-assisted surgery platform.
TransEnterix, which acquired Senhance for $100 million in September 2015, finalized its clerarance bid last month after applying in April.